TAR-200 Granted Priority Review for Non–Muscle-Invasive Bladder Cancer
Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk non–muscle-invasive bladder cancer.
Preliminary Findings Show Tolerability of Carotuximab Combo in mCRPC
The combination of apalutamide to carotuximab showed early signs of tolerability in patients with metastatic castration-resistant prostate cancer.
Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine
Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.
ADCs Are “Legos,” Customize Cancer Treatment By Target, Safety
Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.
Capivasertib Break May Be Needed in Patients With Breast Cancer Experiencing Hyperglycemia
If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.
Tarlatamab Yields Response in Real-World ES-SCLC Population
Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.
Safety Profiles to Look Out for in New Breast Cancer Treatments
New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.
Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS
Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.
Complementary Supportive Care Can Go Far for Patients With Cancer
Getting to the root of patients’ issues can provide support for their cancer journey through accessible means, says Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP.
Olanzapine/Triplet Cuts Chemotherapy-Induced Nausea, Vomiting in Breast Cancer
Those who took olanzapine reported higher levels of satisfaction than patients on placebo.
Panitumumab-Based Chemo Falls Short in Liver-Limited mCRC
Panitumumab plus FOLFIRINOX or mFOLFOX6 failed to yield meaningful responses in liver-limited, RAS/BRAF wild-type unresectable mCRC.
Zanidatamab/Chemo Yields Durable Response in HER2+ Gastroesophageal Cancer
Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.
SUD, Remote Monitoring Appear Feasible for Outpatient BiTE in MM
Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.
Consistent Monitoring Is Key Post Endocrine Therapy in HR+, HER2– mBC
For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.
Irpagratinib/Atezolizumab Active in FGF19+ Advanced HCC
Irpagratinib plus atezolizumab showed durable responses and manageable safety in advanced HCC with FGF19 overexpression, regardless of prior ICI exposure.
Temferon Shows Early Signs of 3-Year Survival, Disease Control in GBM
Treatment with Temferon led to prolonged survival and possible disease control in 2 patients with newly diagnosed glioblastoma multiforme.
KN026/KN046 Combo Yields Durable Responses in HER2+ mBC
KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.
FDA Approves SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC
The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable hepatocellular carcinoma.
High Tumor Volume Linked to CAR T Toxicity in LBCL
Volumetric PET biomarkers may help predict risk of toxicity from CAR T-cell therapy in patients with large B-cell lymphoma, new retrospective data suggest.
Gedatolisib Combos Show Early Activity in mCRPC, Metastatic Breast Cancer
Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.
CAR T-Cell Therapy May Be Moving Up in Myeloma Treatment Sequencing
CAR T-cell therapy is starting to enter treatment conversations sooner with patients with multiple myeloma, according to Nick Barkemeyer, PA-C, MMS.
Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC
Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.
Linvoseltamab Gains FDA Accelerated Approval In R/R Myeloma
The FDA has given accelerated approval to the BiTE, linvoseltamab, for use in the fifth line of therapy for relapsed/refractory multiple myeloma.
Oncology Drugs Approved by the FDA in June
Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.
ICI Rechallenge With Anlotinib May Benefit Pretreated ES-SCLC
Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.
AE Education Aids Breast Cancer Decisions, Says Survivorship Expert
Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.
BMS-986279 Shows Promise in Noninvasive fuc-GM1 Detection for ES-SCLC
Zirconium-89–labeled BMS-986279 demonstrated tumor uptake in fuc-GM1–positive lesions in patients with ES-SCLC.
Retreatment With 177Lu-PSMA-617 May Benefit mCRPC With Sustained Expression
Patients with metastatic CRPC who maintained PSMA expression had a median OS of 14.5 months with 177Lu-PSMA-617 retreatment.
FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel
The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC
